Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Summer;26(4):521-523.
doi: 10.5005/jp-journals-10071-24187.

Extracorporeal Membrane Oxygenation Support in Refractory Multi-organ Failure by 3,4-Methylenedioxymethamphetamine Intoxication ("Ecstasy")

Victoria Ruiz  1 , Foda Rosciani  1 , Indalecio Carboni Bisso  1 , Marcos Las Heras  1
Affiliations
Case Reports

Extracorporeal Membrane Oxygenation Support in Refractory Multi-organ Failure by 3,4-Methylenedioxymethamphetamine Intoxication ("Ecstasy")

Victoria Ruiz et al. Indian J Crit Care Med. 2022 Summer.

Abstract

The substance known as 3,4-methylenedioxymethamphetamine (MDMA) that is commonly named ecstasy is a designer drug used for recreation. The intoxication for MDMA could generate hyperthermia, hepatotoxicity, acute renal failure, cardiovascular toxicity, hyponatremia, serotonin syndrome, coma, and, eventually could lead to, death. There is no antidote available, that is why the treatment is symptomatic and of advanced vital support until the resolution of the case. A case is presented of an adult with multi-organ failure secondary to intoxication for MDMA in whom it was decided to initiate support of oxygenation with extracorporeal membrane oxygenation as a bridge to recovery, with good results.

How to cite this article: Ruiz V, Rosciani F, Bisso IC, Heras ML. Extracorporeal Membrane Oxygenation Support in Refractory Multi-organ Failure by 3,4-Methylenedioxymethamphetamine Intoxication ("Ecstasy"). Indian J Crit Care Med 2022;26(4):521-523.

Keywords: 4-methylenedioxyamphetamine; Extracorporeal membrane oxygenation treatment; Intensive care; N-methyl-3.

PubMed Disclaimer

Conflict of interest statement

Source of support: Nil Conflict of interest: None

References

    1. Kalant H. The pharmacology and toxicology of “ecstasy” (MDMA) and related drugs. CMAJ. 2001;165(7):917–928. 11599334 - PMC - PubMed
    1. Group CEW, Community Epidemiology Work Group. Epidemiologic trends in drug abuse: highlights and executive summary. PsycEXTRA Dataset. 2001 doi: 10.1037/e598902007-001. - DOI
    1. Shannon M. Methylenedioxymethamphetamine (MDMA, “Ecstasy”). Pediatr Emerg Care. 2000;16(5):377–380. doi: 10.1097/00006565-200010000-00022. - DOI - PubMed
    1. Wu D, Otton SV, Inaba T, Kalow W, Sellers EM. Interactions of amphetamine analogs with human liver CYP2D6. Biochem Pharmacol. 1997;53(11):1605–1612. doi: 10.1016/s0006-2952(97)00014-2. - DOI - PubMed
    1. Colado MI, Williams JL, Green AR. The hyperthermic and neurotoxic effects of “Ecstasy” (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br J Pharmacol. 1995;115(7):1281–1289. doi: 10.1111/j.1476-5381.1995.tb15037.x. - DOI - PMC - PubMed

Publication types

LinkOut - more resources